Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel monoclonal antibody therapies for inflammatory and immunology indications. The company's website is www.apogeetrx.com.

Apogee's pipeline comprises multiple antibody programs targeting well-established disease mechanisms with advanced antibody engineering designed to optimize half-life and other therapeutic properties. The company's lead program, zumilokibart (APG777), is an anti-IL-13 antibody in Phase 2 development for atopic dermatitis and Phase 1b evaluation for asthma. Zumilokibart demonstrates an extended half-life of approximately 77 days, supporting potential dosing every three to six months compared to existing therapies requiring more frequent administration. The company is also developing APG279, a combination of zumilokibart and APG990 targeting OX40L, and APG273, combining zumilokibart with APG333 targeting TSLP, both intended for inflammatory and immunology indications. APG808, an anti-IL-4Rα antibody, is in Phase 1b trials for asthma with a demonstrated half-life of approximately 55 days.

The company's therapeutic approach utilizes YTE and LS amino acid modifications to extend antibody half-life, potentially reducing injection burden while maintaining or improving clinical efficacy compared to standard-of-care biologics. Apogee's programs target indications including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease, with potential expansion into additional inflammatory and immunology conditions.

As of February 23, 2026, Apogee had approximately 69.5 million shares of common stock outstanding. The company completed its initial public offering and reorganization on July 13, 2023. Apogee is classified as an accelerated filer and is not a shell company. The company is advancing zumilokibart toward Phase 3 development in atopic dermatitis with a potential launch targeted for 2029, while simultaneously expanding clinical evaluation across additional indications and combination therapies to address significant unmet medical needs in inflammatory and immunology diseases.